The United Kingdom (UK) has become the first country in the world to adopt a COVID-19 antiviral pill developed by Merck and Ridgeback Biotherapeutics for the treament of COVID-19
According to clinical data, the Medicines and Healthcare Products Regulatory Agency (MHRA) suggested that molnupiravir be administered as soon as feasible after a positive COVID-19 test and within five days of the commencement of symptoms.
This is the first oral antiviral medication for COVID-19 to be licensed, a significant step forward in the battle against the pandemic. The approval comes ahead of possible regulatory approval in the United States. This month, US experts will convene to decide on whether molnupiravir should be approved.
Vaccines have so far been the only real weapon the world has had in the fight against COVID-19 which has killed more than 5.2 million people worldwide.
Other treatments, including Gilead’s injected antiviral remdesivir and the generic steroid dexamethasone, are usually administered only after a patient has been admitted to the hospital.